- Increased Scope 1 and 2 GHG emissions by 18% since 2021 (despite emissions intensity per employee decreasing by 15%).
- Potential climate change-related risks including extreme weather events and regulatory changes.
Ionis Pharmaceuticals, Inc.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Ionis Pharmaceuticals, Inc. disclosed greenhouse gas emissions of 5.5K MtCO2e. By scope: Scope 1: 2.7K MtCO2e; Scope 2: 2.8K MtCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
5.5K MtCO2e
2023
Renewable Energy
51%
of total energy
Water Usage
12.85 million gallons
2023
Waste
634 tons
2023
Energy Use
13.2K MWh
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 2.7K MtCO2e |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 2.8K MtCO2e |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Achieved 51% renewable energy use in 2023 with 17% of electricity from renewable sources generated onsite.
- 24% reduction in water use since 2021 (12.85 million gallons in 2023)
- New condensate water collection system for reuse in cooling tower at Carlsbad headquarters.
- New state-of-the-art research and development facility under construction, aiming for LEED Gold certification.
🌱 ESG Focus Areas
Innovation and Drug DiscoveryPatient Advocacy and EngagementWorkplace CultureDiversity, Equity and InclusionEnvironmental SustainabilityGovernance and Integrity